Shen, Y. , Chen, X. , Zhang, H. and Hu, .H. 2024. Long-term cost-effectiveness analysis of onceweekly Semaglutide versus Dulaglutide for the treatment of type 2 diabetes after the renewal of the national drug reimbursement list in China. Health Decision. 2, S1 (Jul. 2024). DOI:https://doi.org/10.54844/hd.2024.0003.